Published in Ther Adv Urol on December 01, 2015
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | NCT01004224
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | NCT01524991
Cabozantinib for Advanced Urothelial Cancer | NCT01688999
Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | NCT01976741
Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium | NCT01551030
Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer | NCT02387996
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer | NCT01118351
Simple and Efficient Stratification of Invasive Bladder Cancer Patients. EBioMedicine (2016) 0.75
Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145. Mol Cancer Ther (2017) 0.75
Autophagy and urothelial carcinoma of the bladder: A review. Investig Clin Urol (2016) 0.75
Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss. Oncotarget (2016) 0.75
A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma. Bladder Cancer (2016) 0.75
Advances in surgical management of muscle invasive bladder cancer. Indian J Urol (2017) 0.75
Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells. Int J Mol Sci (2017) 0.75
Systemic therapy for bladder cancer finally comes into a new age. Future Oncol (2016) 0.75
Overexpression of the transmembrane protein BST-2 induces Akt and Erk phosphorylation in bladder cancer. Oncol Lett (2017) 0.75
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol (2011) 5.95
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet (1999) 5.29
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol (2005) 4.57
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol (2012) 3.98
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol (2014) 3.90
Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res (2009) 3.70
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol (2014) 3.53
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 3.41
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1992) 2.90
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol (2008) 2.88
Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol (2013) 2.83
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem (2010) 2.70
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Polo-like kinases (Plks) and cancer. Oncogene (2005) 2.37
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol (2007) 2.36
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol (2011) 2.10
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther (2012) 2.05
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients. Urol Int (1999) 1.92
Aurora kinase inhibitors--rising stars in cancer therapeutics? Mol Cancer Ther (2010) 1.91
Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol (2010) 1.83
Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol (2015) 1.79
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer (2005) 1.75
Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol (2007) 1.70
Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology (2005) 1.69
A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol (1996) 1.69
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res (2013) 1.62
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol (2012) 1.61
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol (2005) 1.61
T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res (2008) 1.58
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer (2011) 1.51
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol (1997) 1.49
Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer (2009) 1.41
Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res (1995) 1.39
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol (2011) 1.33
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1996) 1.32
The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res (1996) 1.31
Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol (1999) 1.30
Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol (1994) 1.29
A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer (2009) 1.27
Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res (1997) 1.24
Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol (2011) 1.24
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs (2014) 1.23
A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther (2011) 1.22
A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One (2011) 1.21
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol (2015) 1.21
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene (2009) 1.20
Molecular mediators of angiogenesis in bladder cancer. Cancer Res (1998) 1.20
Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol (2010) 1.17
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res (2010) 1.15
Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. Scand J Urol Nephrol (2002) 1.14
Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology (2006) 1.13
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res (2013) 1.12
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int (2009) 1.11
Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol (1991) 1.08
Phase II study of everolimus in metastatic urothelial cancer. BJU Int (2013) 1.07
Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene (2001) 1.06
Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer (1999) 1.05
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer (2013) 1.05
Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. Pharmacol Ther (2014) 1.04
Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift? J Clin Oncol (2011) 1.02
A Network Map of FGF-1/FGFR Signaling System. J Signal Transduct (2014) 1.02
NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol (2014) 1.01
Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol (2009) 1.01
Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res (1995) 1.01
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol (2009) 1.01
Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality. J Natl Compr Canc Netw (2009) 0.98
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol (2013) 0.97
Emerging therapeutic targets in bladder cancer. Cancer Treat Rev (2014) 0.94
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene (2012) 0.93
Optimizing systemic therapy for bladder cancer. J Natl Compr Canc Netw (2013) 0.91
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer (2014) 0.90
Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int (2009) 0.88
Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol (1995) 0.87
Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am (2014) 0.87